At the European Society for Medical Oncology (ESMO) Congress this week, investigators presented data for a new and potentially important drug, ribociclib (Novartis). This oral medication is ...

The team found adding ribociclib, a drug that belongs to a class of CDK4/6 inhibitors, to standard hormone therapy not only ...

Ribociclib – a drug already used to treat breast cancer – may help slow the growth of diffuse hemispheric glioma (DHG), new research has found. Diffuse hemispheric glioma is a rare, high-grade ...

Ribociclib in combination with an aromatose inhibitor for previously untreated advanced or metastatic hormone receptor-positive, her2-negative breast cancer. The NICE appraisal committee wanted to ...

(CercleFinance.com) - Le ribociclib (Kisqali®) de Novartis est reconnu comme traitement adjuvant privilégié de catégorie 1 pour le cancer du sein par les directives de pratique clinique en ...

Many drugs from different chemical classes and therapeutic areas have been shown to inhibit currents mediated via the hERG-coded ion channel, which is strongly correlated to a risk of inducing TdP.

This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) ...

Their research suggested that neoadjuvant therapy with a combination of ribociclib and letrozole could be an alternative to multi-drug neoadjuvant chemotherapy. The trial involved high risk ...

The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It targets high-risk HR-positive, HER2-negative stage II and III patients ...

Expert Rev Clin Pharmacol. 2010;3(3):321-329. Despite a propensity to block hERG channel function, as determined by electrophysiology, for a limited number of compounds no cardiac arrhythmias have ...

Maeve Waldron-Lynch rejoint Tango Therapeutics, Inc. en tant que Senior Vice President, responsable du développement clinique 06/11 CI Bourse Zurich: toujours dans le vert, après la victoire ...